Oxford Biomedica: Edison Open House Healthcare 2022

Oxford Biomedica: Edison Open House Healthcare 2022

Oxford Biomedica — 3 videos in collection

More on this equity

Oxford Biomedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector research and bioprocessing. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

• Tell us about your LentiVector platform and how it positions the company in the market.
• What do you believe are the opportunities in the various vector sectors?
• What are the plans for the advancement of your proprietary pipeline?
• Do you see any changes to your traditional strategy of diversification?
• Are there potential cost-saving opportunities?
• Which milestones should investors focus on in the coming year?

You may also be interested in these:


Oxford Biomedica – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free